What is Fennec Pharmaceuticals Profitability Rank?
Fennec Pharmaceuticals has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Fennec Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2024 was 54.08%. As of today, Fennec Pharmaceuticals's Piotroski F-Score is 8.
Competitive Comparison of Fennec Pharmaceuticals's Profitability Rank
For the Biotechnology subindustry, Fennec Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fennec Pharmaceuticals's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Fennec Pharmaceuticals's Profitability Rank falls into.
Fennec Pharmaceuticals Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Fennec Pharmaceuticals has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Fennec Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Good Sign:
Piotroski F-Score is 8, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Fennec Pharmaceuticals has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Fennec Pharmaceuticals (Fennec Pharmaceuticals) Business Description
Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Executives
| Robert Andrade |
officer: Chief Financial Officer |
C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703 |
| Rosty Raykov |
director, officer: Chief Executive Officer |
C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703 |
| Chris A Rallis |
director |
C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
| Adrian Haigh |
director |
83 ANGLESSA ROAD, BALLSBRIDGE, DUBLIN L2 D04H27 |
| Marco Maria Brughera |
director |
VIALE STEFINI 14, MILANO L6 00000 |
| Khalid Islam |
director |
C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
| Shubh Goel |
officer: Chief Commercial Officer |
1100 MAXWELL, #522, HOBOKEN NJ 07030 |
| Southpoint Capital Advisors Lp |
10 percent owner |
1114 AVENUE OF THE AMERICAS, 22ND FLOOR, NEW YORK NY 10036 |
| Spa Essetifin |
10 percent owner |
VIA SUDAFRICA 20, ROME L6 00144 |
| Jodi A Cook |
director |
PO BOX 816, NEWTOWN PA 08540 |
| Manchester Management Pr, Llc |
10 percent owner |
3 WEST HILL PLACE, BOSTON MA 02114 |
| Francesca Cavazza |
10 percent owner |
VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
| Paolo Cavazza |
10 percent owner |
VIA TESSERETE, 10, LUGANO V8 V8 |
| Silvia Cavazza |
10 percent owner |
VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
| Enrico Cavazza |
10 percent owner |
VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FENC has been successfully added to your